Department of Pharmacy Practice, Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, TX 78363-8202, USA.
Pharmacotherapy. 2012 Dec;32(12):1123-40. doi: 10.1002/phar.1138. Epub 2012 Nov 16.
Drugs account for about 20% of gynecomastia cases in men. As a number of factors can alter the estrogen:androgen ratio, several pathophysiologic mechanisms are associated with drugs causing this disorder. Antiandrogens, protease inhibitors, and nucleoside reverse transcriptase inhibitors are the most common drug causes of gynecomastia, whereas first-generation antipsychotics, spironolactone, verapamil, and cimetidine are less common causes. Other drugs have been reported rarely as causes. Treatment may involve switching to an alternative agent or may require surgery or irradiation if the causative agent cannot be discontinued. We reviewed the literature on drug-induced gynecomastia and provided another perspective by reviewing data from the United States Food and Drug Administration's Adverse Event Reporting System. Epidemiologic studies are needed to provide a more accurate description of the frequency of drug-induced gynecomastia.
药物约占男性乳腺发育症病例的 20%。由于许多因素可以改变雌激素:雄激素的比例,几种病理生理机制与药物引起这种疾病有关。抗雄激素、蛋白酶抑制剂和核苷逆转录酶抑制剂是引起乳腺发育症最常见的药物原因,而第一代抗精神病药、螺内酯、维拉帕米和西咪替丁则是不太常见的原因。其他药物也有报道,但很少见。如果不能停用致病药物,治疗可能需要改用替代药物,或者可能需要手术或放疗。我们回顾了药物引起的乳腺发育症的文献,并通过回顾美国食品和药物管理局不良事件报告系统的数据提供了另一个视角。需要进行流行病学研究,以更准确地描述药物引起的乳腺发育症的频率。